Pyrotinib
- Generic Name
- Pyrotinib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H31ClN6O3
- CAS Number
- 1269662-73-8
- Unique Ingredient Identifier
- CJN36EQM0H
- Background
Pyrotinib is under investigation in clinical trial NCT03756064 (Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
- First Posted Date
- 2015-07-16
- Last Posted Date
- 2021-02-01
- Lead Sponsor
- Hengrui Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT02500199
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸Washington University, Saint Louis, Missouri, United States
🇺🇸University of California, Irvine School of Medicine, Orange, California, United States
A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab
- Conditions
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT02422199
- Locations
- 🇨🇳
307 Hospital Affiliated to Academy Military Medical Science, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer
- First Posted Date
- 2013-09-09
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT01937689
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.